Forty51 Ventures is a venture capital investment firm based in Basel, Switzerland, founded in 2022. The firm focuses on building and investing in early-stage biotech companies across Europe, with a particular emphasis on Switzerland, France, and Germany. Its primary interest lies in the biotech and life science sectors, reflecting a commitment to fostering innovation in these fields.
Allegria Therapeutics is a biotech company focused on advancing the treatment landscape for allergy and inflammatory diseases. The company specializes in research and development that targets mast cells, which play a significant role in these conditions. By addressing these medical challenges, Allegria Therapeutics aims to alleviate the growing burden of such diseases and promote healthier lifestyles for individuals affected by them.
Mysthera Therapeutics
Seed Round in 2023
Mysthera Therapeutics is a biotechnology company focused on developing oral therapeutics to treat complex autoimmune diseases. It aims to reshape the treatment landscape by uniquely and selectively modulating immune cell function in multiple lineages associated with these diseases, with a current focus on glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel, focused on enhancing patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna selects innovative medicines for further development in collaboration with leading contract research organizations, ensuring that hospitals and healthcare providers have access to effective treatment options for patients suffering from various diseases. Through its targeted efforts, Mosanna aims to address significant healthcare challenges and improve therapeutic options for patients.
Mosanna Therapeutics
Seed Round in 2022
Mosanna Therapeutics is a biotechnology company based in Basel, focused on enhancing patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna selects innovative medicines for further development in collaboration with leading contract research organizations, ensuring that hospitals and healthcare providers have access to effective treatment options for patients suffering from various diseases. Through its targeted efforts, Mosanna aims to address significant healthcare challenges and improve therapeutic options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.